Atractylenolide III mitigates polycystic ovary syndrome by activating FDX1-mediated proliferation of ovarian granulocyte cells via PI3K/AKT/mTOR
Nan Zhou, Wei Tai, Wenqiang Lv, Qing He, Shiwen He, Kexin Chen, Qing Wang, Jingbo Zhang, Suyan Li, Yijuan Cao, Xueyan Zhou · 2025
Read Atractylenolide III mitigates polycystic ovary syndrome by activating FDX1-mediated proliferation of ovarian granulocyte cells via PI3K/AKT/mTOR by Nan Zhou, Wei Tai, Wenqiang Lv, Qing He, Shiwen He, Kexin Chen, Qing Wang, Jingbo Zhang, Suyan Li, Yijuan Cao, Xueyan Zhou (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12870249.txt.
Description
Nan Zhou and co-authors test a plant compound for polycystic ovary syndrome in a 2025 study. The syndrome is the most common hormone and fuel disorder in women of child bearing age. The compound comes from a root herb used in Chinese care, and the team trace how it may act.
Fluid and cells from patients showed low levels of a gene called FDX1, tied to cell growth. In mice with the syndrome, the compound fixed cycle timing, egg sac growth, sugar handling, and ovary shape. It also raised FDX1 and a growth marker in the ovary. Cell tests that cut or boosted FDX1 confirm its role in the effect. The chain runs through a known growth signal path in the cells.
Catalog record
| CREATOR | Nan Zhou, Wei Tai, Wenqiang Lv, Qing He, Shiwen He, Kexin Chen, Qing Wang, Jingbo Zhang, Suyan Li, Yijuan Cao, Xueyan Zhou |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |